Ironwood Pharmaceuticals, Inc. (IRWD)
| Market Cap | $806.23M+55.6% |
| Revenue (ttm) | $400.30M |
| Net Income | $149.63M |
| EPS | $0.90 |
| Shares Out | 165.55M |
| PE Ratio | 5.41 |
| Forward PE | 3.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,824,889 |
| Open | $4.83 |
| Previous Close | $4.85 |
| Day's Range | $4.76 - $4.89 |
| 52-Week Range | $2.95 - $5.78 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | $6.17(+26.80%) |
| Earnings Date | Nov 5, 2026 |
About IRWD
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IRWD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IRWD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IRWD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IRWD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IRWD Revenue by Segment
| Collaborative arrangements revenue | $130.75M | 98.87% |
| Royalty | $1.50M | 1.13% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IRWD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IRWD from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IRWD’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat, revenue miss, but raised 2026 guidance driven by record LINZESS sales growth outweigh the miss.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBP | Virtus Biotech ETF | 1.72% |
| FDM | First Trust Dow Jones Select MicroCap Index Fund | 1.20% |
| PEPT | REX Peptide ETF | 0.92% |
| ABLS | Abacus FCF Small Cap Leaders ETF | 0.75% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.65% |
| DSMC | Distillate Small/Mid Cash Flow ETF | 0.57% |
| FSML | Franklin Small Cap Enhanced ETF | 0.38% |
| AESL | Harbor AlphaEdge Small Cap Value ETF | 0.37% |
| AESB | Harbor AlphaEdge Small Cap Core ETF | 0.37% |
| AESG | Harbor AlphaEdge Small Cap Growth ETF | 0.36% |
| SQLV | Royce Quant Small-Cap Quality Value ETF | 0.31% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.30% |
Weight is the stock’s share of each fund’s holdings.
